Skin biopsy has emerged as a valuable minimally invasive diagnostic tool for detecting pathological protein aggregates in neurodegenerative diseases. Unlike cerebrospinal fluid (CSF) collection, which requires lumbar puncture, or neuroimaging, which is expensive and not always available, skin biopsy offers a relatively simple outpatient procedure with growing clinical utility. This page covers the use of skin biopsy for detecting phosphorylated alpha-synuclein (p-syn) and tau protein, with emphasis on its role in differentiating atypical parkinsonian disorders such as corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), Parkinson's disease (PD), and multiple system atrophy (MSA)[1].
The hallmark pathological proteins in neurodegenerative diseases include:
Detecting these proteins outside the central nervous system has diagnostic significance because their presence or absence can help distinguish between different neurodegenerative disorders[2].
The skin is innervated by small nerve fibers that can accumulate pathological proteins through transneural transport or via the peripheral nervous system. Studies have demonstrated that phosphorylated alpha-synuclein can be detected in skin nerve fibers, particularly in autonomic nerve endings. Similarly, tau protein accumulation has been reported in skin fibroblasts and nerve endings in some tauopathies[3].
The standard skin biopsy protocol for neurodegenerative disease assessment involves:
Site Selection: Typically three-millimeter punch biopsies are taken from:
Procedure:
Number of Biopsies: Most protocols use 2-3 biopsy sites, with at least one from a site with high autonomic innervation[4].
The tissue samples undergo:
Phosphorylated alpha-synuclein at Ser129 (p-syn) is the major pathological form found in Lewy bodies and other alpha-synucleinopathies:
| Disease | Sensitivity | Specificity (vs. PSP/CBD) |
|---|---|---|
| PD | 70-90% | 85-95% |
| MSA | 80-95% | 85-95% |
| DLB | 75-90% | 85-95% |
| PSP | <5% | N/A |
| CBD/CBS | <5% | N/A |
Data from multiple studies[5][6]
Positive Result (p-syn detected):
Negative Result (p-syn not detected):
Tau detection in skin biopsies is less well-established than alpha-synuclein detection but shows promise:
Skin biopsy-based tau detection is primarily used in research settings. Clinical applications are still emerging. Some studies have reported:
Skin biopsy is particularly useful in the following clinical scenarios:
Atypical Parkinsonism: When differentiating PD/MSA from PSP/CBS
Dementia Workup: When determining whether dementia is due to Lewy body disease or other causes
Prodromal Detection: Some studies suggest p-syn can be detected before clinical diagnosis in PD[8]
| Method | Invasiveness | Cost | Sensitivity (PD) | Sensitivity (PSP/CBS) |
|---|---|---|---|---|
| Skin Biopsy | Low (minor) | $$ | 70-90% | <5% |
| CSF Biomarkers | Moderate (LP) | $$ | Variable | Moderate |
| DAT Scan | Moderate (radiation) | $$$ | High | Variable |
| Tau PET | High (radiation) | $$$$$ | Low | Moderate |
| Clinical Exam | None | $ | Variable | Variable |
Skin biopsy results should always be interpreted in the context of:
Gibbons C, et al. Skin biopsy detection of phosphorylated alpha-synuclein in patients with synucleinopathies. JAMA Neurology. 2018. ↩︎
Doppler K, et al. Phosphorylated alpha-synuclein in skin nerve fibers is a highly sensitive biomarker for Lewy body disease. Acta Neuropathologica. 2015. ↩︎
Zange L, et al. Skin biopsy in the differentiation of neurodegenerative disorders. Journal of Neurology. 2021. ↩︎
Adler CH, et al. Skin biopsy for detection of phosphorylated alpha-synuclein in Parkinson's disease. Movement Disorders. 2020. ↩︎
Donadio V, et al. Skin nerve phosphorylated alpha-synuclein: a new biomarker for multiple system atrophy. Neurology. 2019. ↩︎
Kim JI, et al. Sensitivity and specificity of skin biopsy for diagnosis of synucleinopathies. Neurology. 2021. ↩︎
Liu AKL, et al. Tau pathology in peripheral tissues: a biomarker for neurodegenerative diseases?. Brain Pathology. 2021. ↩︎
Wang N, et al. Skin biopsy reveals prodromal alpha-synucleinopathy in REM sleep behavior disorder. Annals of Neurology. 2022. ↩︎